Total Funding
60
71
Total FundingSeries B raised
Growth Score
-6 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
8644
Actio Biosciences is a research center that develops drugs for rare diseases.
- David Goldstein: Co-Founder & Chief Executive Officer
- Samuel Collins: Chief Medical Officer
About the Company
Actio Biosciences develops genetics‑led therapies for rare and common diseases. The company applies human genetic insights and precision medicine approaches to identify drug targets and advance a pipeline including candidates for Charcot‑Marie‑Tooth disease type 2C (TRPV4 inhibitor ABS‑0871) and KCNT1‑related epilepsy (ABS‑1230). It conducts
preclinical and Phase 1 studies to evaluate safety, tolerability, and pharmacokinetics for its lead programs. The company also engages in collaboration, licensing, and clinical trial planning to support development and potential expansion into more common indications.
